Jean-Philippe Bertocchio

Assistance Publique - Hôpitaux de Paris
Country flagFrance

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Context Chronic hypoparathyroidism (cHP) is a rare endocrine disorder characterized by hypocalcemia secondary to the insufficient secretion of the parathyroid hormone. Despite the good observance of oral treatment with calcium salts and active vitamin D analogs, and even after adding intermittent subcutaneous injections of teriparatide (IST), some patients are still uncontrolled. Previous studies have suggested that continuous subcutaneous administration of teriparatide (CSAT) may be an option in such cases. Objective The aim of this study was to assess the evolution of biological parameters with CSAT in comparison to previous treatment. Design Retrospective observational study including all patients who received CSAT from 3 tertiary care centers of the Epi-Hypo study. Methods Blood calcium, phosphate, bone remodeling markers, urine calcium, and the evolution of oral treatment were captured from electronic medical records. Quality of life (QoL) was assessed using the Hypoparathyroid Patient Questionnaire (HPQ28). Results Twenty patients were included, 85% were women, and 75% had post-surgery cHP. Total calcium concentration was significantly higher with CSAT than with IST for 73% patients. HPQ28 showed an improvement in three out of the five patients for whom it was assessed. Osteocalcin increased significantly with IST (P = .003), but no difference was observed after initiating CSAT. Conclusion CSAT may be an option for patients with uncontrolled cHP. Further studies need to investigate bone consequences and better characterize the improvement of QoL among these patients.

Year:

2026

Year:

2026

Purpose: Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of the SMARCB1 tumor suppressor. It mainly affects young individuals of African descent with sickle cell trait, and it is resistant to conventional therapies used for other renal cell carcinomas. This study aimed to identify potential biomarkers for early detection and disease monitoring of RMC. Experimental Design: Integrated profiling of primary untreated RMC tumor tissues and paired adjacent kidney controls was performed using RNA sequencing and histone chromatin immunoprecipitation sequencing. The expression of serum cancer antigen 125 (CA-125), was prospectively evaluated in 47 patients with RMC. Functional studies were conducted in RMC cell lines to assess the effects of SMARCB1 reexpression. Results: MUC16, encoding for CA-125, was identified as one of the top upregulated genes in RMC tissues, with concomitant enrichment of active histone marks H3K4me3 and H3K27ac at its promoter. Elevated serum CA-125 levels were found in 31 of 47 (66%) patients with RMC and correlated significantly with metastatic tumor burden (P = 0.03). Functional studies in RMC cell lines demonstrated that SMARCB1 reexpression significantly reduced MUC16 expression. Conclusions: The correlation between serum CA-125 levels and metastatic burden suggests that CA-125 is a clinically relevant biomarker for RMC. These findings support further exploration of CA-125 for disease monitoring and targeted therapeutics in RMC.

Year:

2025

Background Endocrine science remains underrepresented in European Union research programmes despite the fundamental role of hormone health in human well-being. Analysis of the CORDIS database reveals a persistent gap between the societal impact of endocrine disorders and their research prioritization. At national funding level, endocrine societies report limited or little attention of national research funding towards endocrinology. The EndoCompass project—a joint initiative between the European Society of Endocrinology and the European Society of Paediatric Endocrinology—aimed to identify and promote strategic research priorities in endocrine science to address critical hormone-related health challenges. Methods Research priorities were established through comprehensive analysis of the EU CORDIS database covering the Horizon 2020 framework period (2014-2020). Expert consultation in bone and calcium endocrinology was conducted to identify key research priorities, followed by broader stakeholder engagement including society members and patient advocacy groups. Results Research priorities encompass primary hyperparathyroidism, chronic hypoparathyroidism, and rare calcium–phosphate disorders. Key areas include bone as endocrine organ, bone mass acquisition, secondary osteoporosis, and skeletal dysplasias. Special emphasis is placed on cellular senescence, sex-specific differences in disease manifestation, and development of novel diagnostic tools for bone quality assessment. Conclusions This component of the EndoCompass project provides an evidence-based roadmap for strategic research investment. This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society. The findings support the broader EndoCompass objective of aligning research funding with areas of highest potential impact in endocrine health.

Year:

2025

Background At the end of 2023, Bayer AG launched its own internal large language model (LLM), MyGenAssist, based on ChatGPT technology to overcome data privacy concerns. It may offer the possibility to decrease their harshness and save time spent on repetitive and recurrent tasks that could then be dedicated to activities with higher added value. Although there is a current worldwide reflection on whether artificial intelligence should be integrated into pharmacovigilance, medical literature does not provide enough data concerning LLMs and their daily applications in such a setting. Here, we studied how this tool could improve the case documentation process, which is a duty for authorization holders as per European and French good vigilance practices. Objective The aim of the study is to test whether the use of an LLM could improve the pharmacovigilance documentation process. Methods MyGenAssist was trained to draft templates for case documentation letters meant to be sent to the reporters. Information provided within the template changes depending on the case: such data come from a table sent to the LLM. We then measured the time spent on each case for a period of 4 months (2 months before using the tool and 2 months after its implementation). A multiple linear regression model was created with the time spent on each case as the explained variable, and all parameters that could influence this time were included as explanatory variables (use of MyGenAssist, type of recipient, number of questions, and user). To test if the use of this tool impacts the process, we compared the recipients’ response rates with and without the use of MyGenAssist. Results An average of 23.3% (95% CI 13.8%-32.8%) of time saving was made thanks to MyGenAssist (P<.001; adjusted R2=0.286) on each case, which could represent an average of 10.7 (SD 3.6) working days saved each year. The answer rate was not modified by the use of MyGenAssist (20/48, 42% vs 27/74, 36%; P=.57) whether the recipient was a physician or a patient. No significant difference was found regarding the time spent by the recipient to answer (mean 2.20, SD 3.27 days vs mean 2.65, SD 3.30 days after the last attempt of contact; P=.64). The implementation of MyGenAssist for this activity only required a 2-hour training session for the pharmacovigilance team. Conclusions Our study is the first to show that a ChatGPT-based tool can improve the efficiency of a good practice activity without needing a long training session for the affected workforce. These first encouraging results could be an incentive for the implementation of LLMs in other processes.

Year:

2025

Chronic hypoparathyroidism is a rare disease associated with an impaired quality of life. Recommendations suggest frequent monitoring of quality of life, but for French-speaking people, only generic scales are available despite the fact that chronic hypoparathyroidism has specific symptoms and impact. The aim of this study was to adapt and validate the French version of Hypoparathyroid Patient Questionnaire 28 (HPQ28), an already validated tool in patients living with chronic hypoparathyroidism, available in English and German. HPQ28 was translated and back-translated from English into French. Translations were harmonized with the original author. Assessment of psychometric properties of the French version of HPQ28 was performed in the ComPaRe-Epi-Hypo e-cohort, a nationwide cohort of adult patients living with chronic hypoparathyroidism in France. Internal consistency was evaluated using Cronbach’s alpha. Dimensional validity was studied using confirmatory factor analysis (CFA). Construct validity compared the answers from the French version of HPQ28 with those from the EQ-5D-5L, EQ-5D-VAS, and MYMPO2 instruments. Reliability was evaluated by the intra-class correlation coefficient (ICC) of a test–retest within a 2-wk interval. Between August 2023 and August 2024, 183 patients completed HPQ28, EQ-5D, and MYMOP2 scales. The majority (92%) of the participants were women, with a median[IQR] age of 52[44;60]. Etiology of the disease was neck surgery and genetic abnormalities in 82% and 8% of cases, respectively. Internal consistency was good (Cronbach’s alpha 0.93, 95% CI 0.91 to 0.94). CFA found a unidimensional structure of the questionnaire. Construct validity showed positive correlation with MYMOP2 (r = 0.64) and negative correlations with EQ-5D VAS (r = −0.49) and EQ-5D-5L (r = −0.64) scores, as hypothesized. Reliability was adequate, with an ICC of 0.88 (95% CI 0.84 to 0.91). In conclusion, we adapted and validated HPQ28 for French-speaking patients suffering from chronic hypoparathyroidism. It can therefore now be used for both research and clinical follow-up.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Collaborators (19)

Pavlos Msaouel

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Peter Kamenický

Université Paris-Saclay

FRANCE
View details

Rossana Lazcano

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Adalbert Raimann

Medical University of Vienna

AUSTRIA
View details

Patrick Veiga

Institut National de Recherche pour l'Agriculture l'Alimentation et l'Environnement Centre Île-de-France Jouy-en-Josas A

FRANCE
View details

Martin Fassnacht

Head of Division of Endocrinology

University Hospital Würzburg

GERMANY
View details

Zhen Lu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Nizar M Tannir

Professor and Deputy Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sandra Grimm

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Etienne FORMSTECHER

Adjunct Professor

Ecole Polytechnique

FRANCE
View details

Fabrice Larceneux

PSL Research University

FRANCE
View details

Neil Gittoes

Honorary Professor & Consultant

University Hospitals Birmingham NHS Foundation Trust

UNITED KINGDOM
View details

Giannicola Genovese

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cristian Coarfa

Baylor College of Medicine

UNITED STATES
View details

Durga Tripathi

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Niki Zacharias Millward

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Benamouzig

-

FRANCE
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wei-Lien Wang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details